Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activome

The vast majority of the human proteome is yet to be functionally characterized thus hindering ongoing investigations on potential drug resistance mechanisms and advanced treatment options. Chemical proteomics is a powerful solution for enzyme profiling and the development of next generation cancer...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Cancer biology & therapy Ročník 23; číslo 1; s. 136 - 138
Hlavní autori: Lee, Kristi Y., Chau, Cindy H., Price, Douglas K., Figg, William D.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Taylor & Francis 31.12.2022
Taylor & Francis Group
Predmet:
ISSN:1538-4047, 1555-8576, 1555-8576
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:The vast majority of the human proteome is yet to be functionally characterized thus hindering ongoing investigations on potential drug resistance mechanisms and advanced treatment options. Chemical proteomics is a powerful solution for enzyme profiling and the development of next generation cancer therapeutics previously deemed undruggable by small molecules. Within this field, activity-based protein profiling (ABPP) is a specialized technology capable of discriminating enzyme interactions that occur within complex, biological environments. In a recent publication by Lovell et al, the kallikrein-related peptidase (KLK) family of serine proteases that is highly implicated in the progression of prostate cancer (PCa) was subject to ABPP to elucidate enzymatic activities in the presence of enzalutamide. This is the first report of ABPP in PCa and of activity-based chemical probes selective for individual KLKs. Further, the study reveals androgen receptor-dependent activity among KLK proteins, particularly in mediating the invasion of the bone microenvironment.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1538-4047
1555-8576
1555-8576
DOI:10.1080/15384047.2022.2033059